Burghaus, Stefanie; Drazic, Predrag; Wölfler, Monika; Mechsner, Sylvia; Zeppernick, Magdalena; Meinhold-Heerlein, Ivo; Mueller, Michael D; Rothmund, Ralf; Vigano, Paola; Becker, Christian M; Zondervan, Krina T; Beckmann, Matthias W; Fasching, Peter A; Berner-Gatz, Sibylle; Grünewald, Felix S; Hund, Martin; Kastner, Peter; Klammer, Martin; Laubender, Ruediger P; Wegmeyer, Heike; ... (2024). Multicenter evaluation of blood-based biomarkers for the detection of endometriosis and adenomyosis: A prospective non-interventional study. International journal of gynaecology and obstetrics, 164(1), pp. 305-314. Elsevier 10.1002/ijgo.15062
|
Text
Intl_J_Gynecology_Obste_-_2023_-_Burghaus.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (2MB) | Preview |
OBJECTIVE
To evaluate blood-based biomarkers to detect endometriosis and/or adenomyosis across nine European centers (June 2014-April 2018).
METHODS
This prospective, non-interventional study assessed the diagnostic accuracy of 54 blood-based biomarker immunoassays in samples from 919 women (aged 18-45 years) with suspicion of endometriosis and/or adenomyosis versus symptomatic controls. Endometriosis was stratified by revised American Society for Reproductive Medicine stage. Symptomatic controls were "pathologic symptomatic controls" or "pathology-free symptomatic controls". The main outcome measure was receiver operating characteristic-area under the curve (ROC-AUC) and Wilcoxon P values corrected for multiple testing (q values).
RESULTS
CA-125 performed best in "all endometriosis cases" versus "all symptomatic controls" (AUC 0.645, 95% confidence interval [CI] 0.600-0.690, q < 0.001) and increased (P < 0.001) with disease stage. In "all endometriosis cases" versus "pathology-free symptomatic controls", S100-A12 performed best (AUC 0.692, 95% CI 0.614-0.769, q = 0.001) followed by CA-125 (AUC 0.649, 95% CI 0.569-0.729, q = 0.021). In "adenomyosis only cases" versus "symptomatic controls" or "pathology-free symptomatic controls", respectively, the top-performing biomarkers were sFRP-4 (AUC 0.615, 95% CI 0.551-0.678, q = 0.045) and S100-A12 (AUC 0.701, 95% CI 0.611-0.792, q = 0.004).
CONCLUSION
This study concluded that no biomarkers tested could diagnose or rule out endometriosis/adenomyosis with high certainty.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Gynaecology |
UniBE Contributor: |
Mueller, Michael |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0020-7292 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
29 Aug 2023 16:35 |
Last Modified: |
16 Dec 2023 00:13 |
Publisher DOI: |
10.1002/ijgo.15062 |
PubMed ID: |
37635683 |
Uncontrolled Keywords: |
CA-125 S100-A12 adenomyosis blood-based biomarkers diagnosis endometriosis sFRP-4 |
BORIS DOI: |
10.48350/185808 |
URI: |
https://boris.unibe.ch/id/eprint/185808 |
Actions (login required)
 |
Edit item |